my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
21-12-2010: Evotec AG announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca), in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells. The license gives MedImmune exclusive access to a portfolio of research programs and represents the first deal executed by Evotec on beta cell regeneration assets and capabilities.
The agreement triggers an upfront payment of € 5 million. Further on, additional deferred payments including potential milestone payments of up to € 254 million as well as royalties are agreed. The milestone payments will be due upon achievement of certain clinical as well as regulatory and commercial events. Further milestone payments may be achieved with the approval of additional indications and programs. Evotec will also receive research payments to support further in vivo and in vitro pharmacology efforts conducted in collaboration with MedImmune.
Watchlist
This is where you can add this news to your personal favourites
Belfer Institute and Evotec establish collaboration in oncology
The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG (EVT) announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms. The goal of the collaboration is to validate emerging ... more
Evotec expands compound management capability to East Coast of the United States
Evotec AG announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand the offering of its Compound Management Services on the East Coast of the United States. Scott Snyder, Executive Vice President Compound Management of Evotec, commented: ' ... more
Evotec achieves milestone in drug discovery collaboration with Ono
Evotec AG announced that a compound identified and optimised in a research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone. This collaboration project was initiated in March 2008. Evotec co ... more
Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more
Evotec announces metabolic disease alliance with MedImmune
Evotec AG announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca), in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells. The l ... more
Evotec Completes Acquisition of DeveloGen
Following the successful fulfilment of various Closing conditions, the sellers of 99.3% of the shares in DeveloGen AG transferred their shares to Evotec AG. Evotec AG issues 6,750,014 new Evotec Shares from its authorized capital as part consideration for the transaction. Following the re ... more
DeveloGen AG announced that it will receive US$ 500,000 from the Juvenile Diabetes Research Foundation, New York, USA (JDRF). The funds are dedicated to aide in the research of mechanisms for the protection of beta cells. In this two year project titled "Development of Novel Therapeutic Ag ... more
Evotec expands collaboration with MedImmune, receives milestone payment
Evotec AG announced that it has expanded the scope of its collaboration with MedImmune after hitting a key milestone. Evotec achieved a milestone payment of EUR0.5 m. The milestone triggers a commercial license granted to MedImmune and an extension of the diabetes and beta cell regeneration ... more
Evotec announces metabolic disease alliance with MedImmune
Evotec AG announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca), in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells. The l ... more
Micromet Buys Out MedImmune’s Remaining Rights to Blinatumomab
Micromet, Inc. announced that it has signed an agreement with MedImmune, LLC to buy out MedImmune’s rights to blinatumomab in North America, and to terminate the collaboration agreement signed in 2003 under which MedImmune had been granted the right to develop and commericalize blinatumoma ... more
MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory ... more
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
